ChengDa Pharmaceuticals Co. Ltd.
ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food… Read more
ChengDa Pharmaceuticals Co. Ltd. (301201) - Total Assets
Latest total assets as of June 2025: CN¥2.41 Billion CNY
Based on the latest financial reports, ChengDa Pharmaceuticals Co. Ltd. (301201) holds total assets worth CN¥2.41 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ChengDa Pharmaceuticals Co. Ltd. - Total Assets Trend (2019–2024)
This chart illustrates how ChengDa Pharmaceuticals Co. Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ChengDa Pharmaceuticals Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
ChengDa Pharmaceuticals Co. Ltd.'s total assets of CN¥2.41 Billion consist of 58.1% current assets and 41.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.3% |
| Accounts Receivable | CN¥94.68 Million | 3.9% |
| Inventory | CN¥135.27 Million | 5.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥36.51 Million | 1.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how ChengDa Pharmaceuticals Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ChengDa Pharmaceuticals Co. Ltd.'s current assets represent 58.1% of total assets in 2024, an increase from 41.6% in 2019.
- Cash Position: Cash and equivalents constituted 7.3% of total assets in 2024, down from 12.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 3.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 5.6% of total assets.
ChengDa Pharmaceuticals Co. Ltd. Competitors by Total Assets
Key competitors of ChengDa Pharmaceuticals Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
ChengDa Pharmaceuticals Co. Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - ChengDa Pharmaceuticals Co. Ltd. generates 0.14x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - ChengDa Pharmaceuticals Co. Ltd. is currently not profitable relative to its asset base.
ChengDa Pharmaceuticals Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.95 | 9.93 | 22.78 |
| Quick Ratio | 7.99 | 9.16 | 21.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.26 Billion | CN¥ 1.37 Billion | CN¥ 1.69 Billion |
ChengDa Pharmaceuticals Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between ChengDa Pharmaceuticals Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.01 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -0.8% |
| Total Assets | CN¥2.44 Billion |
| Market Capitalization | $414.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values ChengDa Pharmaceuticals Co. Ltd.'s assets below their book value (0.17 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: ChengDa Pharmaceuticals Co. Ltd.'s assets decreased by 0.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for ChengDa Pharmaceuticals Co. Ltd. (2019–2024)
The table below shows the annual total assets of ChengDa Pharmaceuticals Co. Ltd. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.44 Billion | -0.77% |
| 2023-12-31 | CN¥2.46 Billion | +5.75% |
| 2022-12-31 | CN¥2.32 Billion | +239.84% |
| 2021-12-31 | CN¥683.23 Million | +27.90% |
| 2020-12-31 | CN¥534.21 Million | -2.26% |
| 2019-12-31 | CN¥546.56 Million | -- |